[
  {
    "ts": "2026-02-24T01:50:00+00:00",
    "headline": "Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.",
    "summary": "Is this the best way to cash in on the weight-loss gold rush?",
    "url": "https://www.fool.com/investing/2026/02/23/got-5000-viking-therapeutics-might-be-a-weightloss/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "b570b168-e5bd-3c20-8f00-9f73b1936546",
      "content": {
        "id": "b570b168-e5bd-3c20-8f00-9f73b1936546",
        "contentType": "STORY",
        "title": "Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.",
        "description": "",
        "summary": "Is this the best way to cash in on the weight-loss gold rush?",
        "pubDate": "2026-02-24T01:50:00Z",
        "displayTime": "2026-02-24T01:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/8cb3e7d41323dda7fd999091cfad559b",
          "originalWidth": 1400,
          "originalHeight": 738,
          "caption": "A person surrounded by stock monitors stands with both fists raised in the air.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3yBXzk4FUvsgR0VJ93gOsA--~B/aD03Mzg7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/8cb3e7d41323dda7fd999091cfad559b.cf.webp",
              "width": 1400,
              "height": 738,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U3weefRt6VjSNRthUdJc8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/8cb3e7d41323dda7fd999091cfad559b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/got-5000-viking-therapeutics-might-be-a-weightloss/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/got-5-000-viking-therapeutics-015000209.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T03:12:53+00:00",
    "headline": "CagriSema Setback Tests Novo Nordisk Obesity Ambitions And Growth Story",
    "summary": "Novo Nordisk (CPSE:NOVO B) reported that its next generation obesity drug candidate CagriSema did not meet the primary goal of non inferiority versus Eli Lilly's tirzepatide in a head to head Phase 3 trial. The readout from this pivotal study challenges Novo Nordisk's efforts to strengthen its position in the competitive market for injectable weight loss therapies. The result introduces fresh questions around CagriSema's commercial potential and the company's roadmap for future obesity...",
    "url": "https://finance.yahoo.com/news/cagrisema-setback-tests-novo-nordisk-031253330.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "16955788-3c9d-3a6f-8da1-ee8f9f9ef0d2",
      "content": {
        "id": "16955788-3c9d-3a6f-8da1-ee8f9f9ef0d2",
        "contentType": "STORY",
        "title": "CagriSema Setback Tests Novo Nordisk Obesity Ambitions And Growth Story",
        "description": "",
        "summary": "Novo Nordisk (CPSE:NOVO B) reported that its next generation obesity drug candidate CagriSema did not meet the primary goal of non inferiority versus Eli Lilly's tirzepatide in a head to head Phase 3 trial. The readout from this pivotal study challenges Novo Nordisk's efforts to strengthen its position in the competitive market for injectable weight loss therapies. The result introduces fresh questions around CagriSema's commercial potential and the company's roadmap for future obesity...",
        "pubDate": "2026-02-24T03:12:53Z",
        "displayTime": "2026-02-24T03:12:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pVOKMAerbRsXv56pHka6Lw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmyGBi4taxQExvvwka_9KQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cagrisema-setback-tests-novo-nordisk-031253330.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cagrisema-setback-tests-novo-nordisk-031253330.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T05:11:40+00:00",
    "headline": "Analysis-Novo's stumbles burnish Lilly's widening lead in weight-loss drugs",
    "summary": "By Maggie Fick and Bhanvi Satija LONDON, Feb 24 (Reuters) - With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed was to give it",
    "url": "https://finance.yahoo.com/news/analysis-novos-stumbles-burnish-lillys-051140762.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "b90ce395-444c-3e61-9e14-abf5aa1249d9",
      "content": {
        "id": "b90ce395-444c-3e61-9e14-abf5aa1249d9",
        "contentType": "STORY",
        "title": "Analysis-Novo's stumbles burnish Lilly's widening lead in weight-loss drugs",
        "description": "",
        "summary": "By Maggie Fick and Bhanvi Satija LONDON, Feb 24 (Reuters) - With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed was to give it",
        "pubDate": "2026-02-24T05:11:40Z",
        "displayTime": "2026-02-24T05:11:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/6a12d1ffc5ecbb3eb7f7e230ae800ab5",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "FILE PHOTO: The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7leTF2vBE1iGr.gatcaFvw--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/6a12d1ffc5ecbb3eb7f7e230ae800ab5.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d80u2lNj74jWqLsOgdWExg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/6a12d1ffc5ecbb3eb7f7e230ae800ab5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysis-novos-stumbles-burnish-lillys-051140762.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysis-novos-stumbles-burnish-lillys-051140762.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T06:04:56+00:00",
    "headline": "Is Eli Lilly Stock Underperforming the S&P 500?",
    "summary": "Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.",
    "url": "https://www.barchart.com/story/news/378781/is-eli-lilly-stock-underperforming-the-s-p-500",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "4ab1a2b9-bc99-3c9c-8870-c1bbdd947666",
      "content": {
        "id": "4ab1a2b9-bc99-3c9c-8870-c1bbdd947666",
        "contentType": "STORY",
        "title": "Is Eli Lilly Stock Underperforming the S&P 500?",
        "description": "",
        "summary": "Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.",
        "pubDate": "2026-02-24T06:04:56Z",
        "displayTime": "2026-02-24T06:04:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/0d9ac77c949cf1810e20427fc62c5fa4",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Lilly(Eli) & Co logo on building-by Michael Vi via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rRoaSjcBmk5ZphUbBkOsTw--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/0d9ac77c949cf1810e20427fc62c5fa4.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/81k.kKF6ujx761TcDBUQuA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/0d9ac77c949cf1810e20427fc62c5fa4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/378781/is-eli-lilly-stock-underperforming-the-s-p-500",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-stock-underperforming-p-060456041.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T10:19:40+00:00",
    "headline": "JPM downgrades Novo on disappointing CagriSema obesity trial results, shares dip",
    "summary": "Investing.com -- JPMorgan downgraded Novo Nordisk (CSE:NOVOb) (NYSE:NVO) to Neutral from Overweight after disappointing late-stage REDEFINE-4 results for its obesity drug CagriSema showed weaker-than-expected competitiveness versus Eli Lilly’s (NYSE:LLY) Zepbound.",
    "url": "https://finance.yahoo.com/news/jpm-downgrades-novo-disappointing-cagrisema-101940459.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "eb5641ba-2841-30f9-979c-5309c3cd1c16",
      "content": {
        "id": "eb5641ba-2841-30f9-979c-5309c3cd1c16",
        "contentType": "STORY",
        "title": "JPM downgrades Novo on disappointing CagriSema obesity trial results, shares dip",
        "description": "",
        "summary": "Investing.com -- JPMorgan downgraded Novo Nordisk (CSE:NOVOb) (NYSE:NVO) to Neutral from Overweight after disappointing late-stage REDEFINE-4 results for its obesity drug CagriSema showed weaker-than-expected competitiveness versus Eli Lilly’s (NYSE:LLY) Zepbound.",
        "pubDate": "2026-02-24T10:19:40Z",
        "displayTime": "2026-02-24T10:19:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jpm-downgrades-novo-disappointing-cagrisema-101940459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm-downgrades-novo-disappointing-cagrisema-101940459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JPM"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]